Glaxo Pharma Financial Statements

Glaxo Pharma (GLAXO) reported revenue of ₹38.95B in FY2025 with net income of ₹9.28B. Total assets stood at ₹41.08B and free cash flow was ₹12.67B.

Glaxo Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2019 – FY 2025

Item	Chart	2019	2020	2021	2024	2025
Revenue		31.28B	32.24B	33.09B	35.76B	38.95B
Cost of Rev. Cost of Revenue		-13.58B	-13.08B	-13.13B	-13.35B	-13.91B
Gross Profit		17.70B	19.17B	19.97B	22.42B	25.04B
SGA Sales, General & Admin		-11.69B	-12.59B	-11.91B	-12.10B	-11.81B
Op. Income Operating Income		5.52B	5.75B	7.27B	9.62B	12.57B
PBT Profit Before Tax		6.83B	3.06B	5.50B	8.16B	12.60B
Net Income		4.45B	932.05M	3.58B	5.90B	9.28B
Dil. Shares Diluted Shares		169.41M	169.41M	169.41M	169.38M	169.39M
Diluted EPS		26.29	5.50	21.14	34.83	54.76

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Glaxo Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Glaxo Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		22.03B	37.08B	24.94B	27.98B	34.10B
Non-curr. assets Total non-current assets		9.11B	9.25B	8.32B	7.58B	6.98B
Total assets		31.13B	46.33B	33.27B	35.57B	41.08B
Curr. liabilities Total current liabilities		13.32B	16.98B	13.26B	15.25B	19.05B
Non-curr. liab. Total non-current liabilities		2.82B	2.72B	2.59B	2.54B	2.52B
Total liabilities		16.14B	19.70B	15.85B	17.79B	21.57B
Total equity		14.99B	26.63B	17.41B	17.78B	19.51B
Total liab. & eq. Total liabilities & equity		31.13B	46.33B	33.27B	35.57B	41.08B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Glaxo Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Glaxo Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		7.23B	7.79B	8.36B	9.60B	12.55B
Operating CF Cash flow Operating Activities		5.78B	8.11B	4.84B	5.82B	12.90B
Capex Investments in PPE		-442.27M	-346.40M	-440.40M	-312.22M	-230.22M
Investing CF Cash flow Investing Activities		4.19B	-4.06B	8.08B	87.12M	-458.01M
Dividend Paid		-6.78B	-5.07B	-15.26B	-5.42B	-7.49B
Financing CF Cash flow Financing Activities		-6.96B	-5.24B	-15.43B	-5.61B	-7.69B
Cash (start) Cash at beginning of period		1.05B	4.05B	2.86B	349.41M	641.71M
Cash (end) Cash at end of period		4.05B	2.86B	349.40M	641.71M	5.39B
FCF Free Cash Flow		5.34B	7.76B	4.40B	5.51B	12.67B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Glaxo Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025